Get the Stockscreener App
10.40
2.26%
+0.23
After Hours:
10.40
Olema Pharmaceuticals Inc stock is currently priced at $10.40, with a 24-hour trading volume of 944.91K.
It has seen a +2.26% increased in the last 24 hours and a -4.50% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $9.90 pivot point. If it approaches the $10.59 resistance level, significant changes may occur.
Previous Close:
$10.17
Open:
$10.15
24h Volume:
944.91K
Market Cap:
$581.71M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-4.3154
EPS:
-2.41
Net Cash Flow:
$-83.73M
1W Performance:
+2.46%
1M Performance:
-4.50%
6M Performance:
-30.39%
1Y Performance:
+91.53%
1D Range:
$9.93
$10.78
52W Range:
$5.00
$17.79
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
415-651-3316
Address
512 2nd Street, 4th Floor, San Francisco
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Olema Oncology to Participate in Upcoming Investor Conferences in May
GlobeNewswire Inc.
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
GlobeNewswire Inc.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
GlobeNewswire Inc.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Olema Pharmaceuticals Inc (OLMA) Net Income 2024
OLMA net income (TTM) was -$96.66 million for the quarter ending December 31, 2023, a +7.76% increase year-over-year.
Olema Pharmaceuticals Inc (OLMA) Cash Flow 2024
OLMA recorded a free cash flow (TTM) of -$83.73 million for the quarter ending December 31, 2023, a -1.58% decrease year-over-year.
Olema Pharmaceuticals Inc (OLMA) Earnings per Share 2024
OLMA earnings per share (TTM) was -$2.15 for the quarter ending December 31, 2023, a +17.94% growth year-over-year.
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
3.18%
Cap:
|
Volume (24h):